(Q48053718)

English

Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China

scientific article published in February 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

chronic hepatitis B

1 reference

based on heuristic

inferred from title

author name string

Xiao-Guang Li

1

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Bao-Ming Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Jie Xu

3

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Xue-En Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Hai Ding

5

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Tong Li

6

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

publication date

1 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Journal of Medical Virology

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

84

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

2

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

207-216

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Hepatitis B virus genetic diversity

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Hepatitis B virus: molecular virology and common mutants

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Characterization of naturally occurring and Lamivudine-induced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Inhibition of hepatitis B virus polymerase by entecavir

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Cellular and virological mechanisms of HBV drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

HBV drug resistance: mechanisms, detection and interpretation

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Hepatitis B virus escape mutants induced by antiviral therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Mutations affecting the replication capacity of the hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Infections by hepatitis B surface antigen gene mutants in Europe and North America

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Primary infection with a lamivudine-resistant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Management and prevention of drug resistance in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Molecular epidemiology of hepatitis B virus mutants

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Mutations of the surface protein of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23182

21 January 2018

Identifiers

10.1002/JMV.23182

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/22170539

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48053718&oldid=2182793924"